You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuinapril
Accession NumberDB00881  (APRD00523)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionQuinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure.
Structure
Thumb
Synonyms
Quinapril
Quinaprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AccuprilTablet, film coated40 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated10 mg/1OralCardinal Health1991-11-19Not applicableUs
AccuprilTablet, film coated5 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated20 mg/1OralCardinal Health1991-11-19Not applicableUs
AccuprilTablet, film coated10 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated40 mg/1Oralbryant ranch prepack1991-11-19Not applicableUs
AccuprilTablet, film coated20 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupril 5mg TabTablet5 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 10mgTablet10 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 20mgTablet20 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 40mgTablet40 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Gd-quinaprilTablet5 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinaprilTablet10 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinaprilTablet20 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinaprilTablet40 mgOralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
PMS-quinaprilTablet5 mgOralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinaprilTablet10 mgOralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinaprilTablet20 mgOralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinaprilTablet40 mgOralPharmascience Inc2013-11-18Not applicableCanada
QuinaprilTablet40 mgOralPro Doc Limitee2013-11-28Not applicableCanada
QuinaprilTablet5 mgOralPro Doc Limitee2013-11-28Not applicableCanada
QuinaprilTablet10 mgOralPro Doc Limitee2013-11-28Not applicableCanada
QuinaprilTablet20 mgOralPro Doc Limitee2013-11-28Not applicableCanada
Quinapril HydrochlorideTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.1991-11-19Not applicableUs
Quinapril HydrochlorideTablet, film coated40 mg/1OralGreenstone LLC1991-11-19Not applicableUs
Quinapril HydrochlorideTablet, film coated5 mg/1OralCarilion Materials Management1991-11-19Not applicableUs
Quinapril HydrochlorideTablet, film coated5 mg/1OralGreenstone LLC1991-11-19Not applicableUs
Quinapril HydrochlorideTablet, film coated10 mg/1OralCarilion Materials Management1991-11-19Not applicableUs
Quinapril HydrochlorideTablet, film coated10 mg/1OralGreenstone LLC1991-11-19Not applicableUs
Quinapril HydrochlorideTablet, film coated20 mg/1OralCarilion Materials Management1991-11-19Not applicableUs
Quinapril HydrochlorideTablet, film coated20 mg/1OralGreenstone LLC1991-11-19Not applicableUs
Ran-quinaprilTablet40 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinaprilTablet5 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinaprilTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinaprilTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quinaprilTablet20 mgOralApotex Inc2013-07-02Not applicableCanada
Apo-quinaprilTablet40 mgOralApotex Inc2013-07-02Not applicableCanada
Apo-quinaprilTablet5 mgOralApotex Inc2013-07-02Not applicableCanada
Apo-quinaprilTablet10 mgOralApotex Inc2013-07-02Not applicableCanada
QuinaprilTablet5 mg/1OralAv Kare, Inc.2012-08-022016-01-21Us
QuinaprilTablet40 mg/1OralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
QuinaprilTablet, film coated20 mg/1OralAurobindo Pharma Limited2013-04-29Not applicableUs
QuinaprilTablet40 mg/1OralLupin Pharmaceuticals, Inc.2014-08-01Not applicableUs
QuinaprilTablet5 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
QuinaprilTablet5 mg/1OralRebel Distributors Corp2010-02-26Not applicableUs
QuinaprilTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2005-03-03Not applicableUs
QuinaprilTablet, film coated10 mg/1OralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
QuinaprilTablet40 mg/1OralA S Medication Solutions2012-01-20Not applicableUs
QuinaprilTablet5 mg/1OralAv Pak2014-08-052016-03-11Us
QuinaprilTablet, film coated20 mg/1OralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
QuinaprilTablet10 mg/1OralBlue Point Laboratories2014-02-25Not applicableUs
QuinaprilTablet40 mg/1OralLupin Pharmaceuticals, Inc.2007-02-262016-04-30Us
QuinaprilTablet, film coated20 mg/1OralA S Medication Solutions2013-04-29Not applicableUs
QuinaprilTablet20 mg/1OralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
QuinaprilTablet5 mg/1OralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
QuinaprilTablet, film coated40 mg/1Oralbryant ranch prepack2010-02-25Not applicableUs
QuinaprilTablet10 mg/1OralAv Kare, Inc.2012-08-022016-01-21Us
QuinaprilTablet40 mg/1OralCardinal Health2012-01-20Not applicableUs
QuinaprilTablet, film coated40 mg/1OralAurobindo Pharma Limited2013-04-29Not applicableUs
QuinaprilTablet5 mg/1OralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
QuinaprilTablet10 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
QuinaprilTablet10 mg/1OralRebel Distributors Corp2010-02-26Not applicableUs
QuinaprilTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2005-03-07Not applicableUs
QuinaprilTablet, film coated20 mg/1OralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
QuinaprilTablet5 mg/1OralBlue Point Laboratories2014-02-25Not applicableUs
QuinaprilTablet10 mg/1OralA S Medication Solutions2012-01-20Not applicableUs
QuinaprilTablet10 mg/1OralAv Pak2014-08-052016-03-11Us
QuinaprilTablet, film coated40 mg/1OralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
QuinaprilTablet10 mg/1OralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
QuinaprilTablet, film coated5 mg/1OralAurobindo Pharma Limited2013-04-29Not applicableUs
QuinaprilTablet, film coated40 mg/1OralA S Medication Solutions2013-04-29Not applicableUs
QuinaprilTablet40 mg/1OralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
QuinaprilTablet10 mg/1OralA S Medication Solutions2012-01-20Not applicableUs
QuinaprilTablet20 mg/1OralAv Kare, Inc.2012-08-022016-01-21Us
QuinaprilTablet, film coated5 mg/1OralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
QuinaprilTablet40 mg/1OralBlue Point Laboratories2014-02-252016-04-30Us
QuinaprilTablet10 mg/1OralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
QuinaprilTablet20 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
QuinaprilTablet5 mg/1OralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
QuinaprilTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2007-11-28Not applicableUs
QuinaprilTablet, film coated40 mg/1OralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
QuinaprilTablet20 mg/1OralAv Pak2014-08-052016-03-11Us
QuinaprilTablet10 mg/1OralProficient Rx LP2012-01-20Not applicableUs
QuinaprilTablet40 mg/1OralBlue Point Laboratories2014-07-18Not applicableUs
QuinaprilTablet, film coated20 mg/1OralA S Medication Solutions2013-04-29Not applicableUs
QuinaprilTablet40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-02-26Not applicableUs
QuinaprilTablet20 mg/1OralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
QuinaprilTablet, film coated10 mg/1OralAurobindo Pharma Limited2013-04-29Not applicableUs
QuinaprilTablet20 mg/1OralA S Medication Solutions2012-01-20Not applicableUs
QuinaprilTablet40 mg/1OralAv Kare, Inc.2012-08-022016-01-21Us
QuinaprilTablet, film coated10 mg/1OralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
QuinaprilTablet20 mg/1OralBlue Point Laboratories2014-02-25Not applicableUs
QuinaprilTablet20 mg/1OralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
QuinaprilTablet40 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
QuinaprilTablet10 mg/1OralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
QuinaprilTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2005-07-22Not applicableUs
QuinaprilTablet, film coated20 mg/1Oralbryant ranch prepack2010-02-25Not applicableUs
QuinaprilTablet, film coated40 mg/1OralA S Medication Solutions2013-04-29Not applicableUs
QuinaprilTablet40 mg/1OralAv Pak2014-08-052016-03-11Us
QuinaprilTablet, film coated5 mg/1OralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
QuinaprilTablet20 mg/1OralAmerican Health Packaging2015-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AccuprinPfizer (Italy)
AccuproPfizer (Austria, Denmark, Finland, Germany, Hungary, Ireland, Sweden, Switzerland, United Kingdom, Ukraine), Godecke (Czech Republic, Germany, Poland, Russia), Parke, Davis (Germany)
AcequinNot Available
AcuitelNot Available
KorecNot Available
QuinazilNot Available
Brand mixtures
NameLabellerIngredients
AccureticParke Davis Div Of Pfizer Inc
Accuretic 10/12.5 mgPfizer Canada Inc
Accuretic 20/12.5 mgPfizer Canada Inc
Accuretic 20/25 mgPfizer Canada Inc
Apo-quinapril/hctzApotex Inc
Gd-quinapril HctzGenmed A Division Of Pfizer Canada Inc
Quinapril and Hydrochlorothiazide 10/12.5Cipla USA Inc.
Quinapril and Hydrochlorothiazide 20/12.5Cipla USA Inc.
Quinapril and Hydrochlorothiazide 20/25Cipla USA Inc.
Quinapril HCl and HydrochlorothiazideGavis Pharmaceuticals, LLC.
Quinapril Hydrochloride and HydrochlorothiazideCamber Pharmaceuticals
Quinapril Hydrochloride/hydrochlorothiazideLake Erie Medical DBA Quality Care Products LLC
Salts
Name/CASStructureProperties
Quinapril Hydrochloride
82586-55-8
Thumb
  • InChI Key: IBBLRJGOOANPTQ-JKVLGAQCSA-N
  • Monoisotopic Mass: 474.192149819
  • Average Mass: 474.977
DBSALT000465
Categories
UNIIRJ84Y44811
CAS number85441-61-8
WeightAverage: 438.5161
Monoisotopic: 438.21547208
Chemical FormulaC25H30N2O5
InChI KeyJSDRRTOADPPCHY-HSQYWUDLSA-N
InChI
InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[[email protected]]1C(O)=O
Pharmacology
IndicationFor the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Structured Indications
PharmacodynamicsQuinapril is a nonpeptide, non-sulfhydryl prodrug that is deesterified to quinaprilat (quinapril diacid), its major active metabolite following oral administration. Quinaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of quinaprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Quinaprilat, the principle active metabolite of quinapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
AbsorptionPeak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Quinapril
Not Available
QuinaprilatDetails
Route of eliminationQuinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose
Half lifeElimination half life is 2 hours with a prolonged terminal phase of 25 hours.
ClearanceNot Available
ToxicityOverdose may lead to severe hypotension. LD50=1739mg/kg (orally in mice). The most common adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea, fatigue, and nausea/vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Quinapril Metabolism PathwayDrug metabolismSMP00596
Quinapril Action PathwayDrug actionSMP00153
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Quinapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Quinapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Quinapril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Quinapril is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Quinapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Quinapril is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Quinapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Quinapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinapril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Quinapril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Quinapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Quinapril.Approved, Withdrawn
AmbrisentanQuinapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Quinapril.Experimental
AmifostineQuinapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Quinapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Quinapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Quinapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Quinapril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Quinapril is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quinapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quinapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Quinapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Quinapril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Quinapril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Quinapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Quinapril is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Quinapril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Quinapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Quinapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Quinapril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Quinapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Quinapril is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Quinapril is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Quinapril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Quinapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Azapropazone.Withdrawn
AzathioprineQuinapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Quinapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Quinapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Quinapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Quinapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Quinapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Quinapril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quinapril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quinapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Quinapril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Benoxaprofen.Withdrawn
BepridilQuinapril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quinapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Quinapril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Quinapril is combined with Betulinic Acid.Investigational
BimatoprostQuinapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quinapril.Approved
BoceprevirThe serum concentration of Quinapril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Quinapril is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Quinapril.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Quinapril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Quinapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Quinapril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Quinapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Quinapril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Quinapril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Quinapril is combined with Bupivacaine.Approved, Investigational
BupranololQuinapril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Quinapril.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Quinapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Quinapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Quinapril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Captopril.Approved
CarbamazepineThe metabolism of Quinapril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Quinapril is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Quinapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Quinapril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Quinapril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Quinapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Celecoxib.Approved, Investigational
CeliprololQuinapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Quinapril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Quinapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quinapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Quinapril.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Chlorpromazine.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Quinapril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quinapril.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Cilnidipine.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Quinapril.Approved, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
CiprofloxacinQuinapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Quinapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Quinapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Quinapril is combined with Clofarabine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Quinapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quinapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Quinapril is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Quinapril is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Quinapril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Quinapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Quinapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Quinapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Quinapril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Quinapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Quinapril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Quinapril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Quinapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Quinapril.Investigational
DebrisoquinQuinapril may increase the hypotensive activities of Debrisoquin.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Quinapril.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Quinapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Quinapril.Investigational
DeserpidineQuinapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Quinapril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Quinapril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quinapril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Quinapril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Quinapril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Quinapril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Quinapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Quinapril.Approved
DihydralazineQuinapril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Quinapril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Quinapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Quinapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Quinapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quinapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Quinapril.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Quinapril.Approved, Investigational, Vet Approved
DrospirenoneQuinapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Droxicam.Approved
DuloxetineQuinapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Quinapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Quinapril.Approved
E6201The risk or severity of adverse effects can be increased when Quinapril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Quinapril is combined with Ebselen.Investigational
EfonidipineQuinapril may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quinapril.Approved, Vet Approved
EnalaprilatQuinapril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Quinapril.Approved, Investigational
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Quinapril.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Quinapril.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Quinapril.Approved
EpoprostenolQuinapril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quinapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Quinapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Quinapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Quinapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Quinapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Quinapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Quinapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Quinapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Quinapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Quinapril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Quinapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Quinapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Quinapril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Quinapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Quinapril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Quinapril is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Quinapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Quinapril is combined with Fimasartan.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Quinapril.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Quinapril is combined with Floctafenine.Approved, Withdrawn
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Quinapril.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Quinapril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Quinapril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quinapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Quinapril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Quinapril.Approved, Vet Approved
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Quinapril.Investigational
GarlicThe serum concentration of Quinapril can be decreased when it is combined with Garlic.Approved
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Quinapril.Withdrawn
GuanabenzGuanabenz may increase the hypotensive activities of Quinapril.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Quinapril.Approved
GuanethidineQuinapril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Quinapril is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Quinapril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
HexamethoniumQuinapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Quinapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Quinapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Quinapril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Quinapril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Quinapril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Quinapril.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Quinapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Quinapril.Approved
IloprostIloprost may increase the hypotensive activities of Quinapril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quinapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Quinapril.Approved
IndenololQuinapril may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Quinapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Indoprofen.Withdrawn
IndoraminQuinapril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Quinapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Quinapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quinapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Quinapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Quinapril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Kebuzone.Experimental
KetanserinQuinapril may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Quinapril.Approved
LacidipineQuinapril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Quinapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Quinapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Quinapril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Quinapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Quinapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Quinapril is combined with Levobupivacaine.Approved
LevodopaQuinapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Quinapril is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Quinapril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quinapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Quinapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Quinapril.Approved
LofexidineQuinapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Quinapril.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Quinapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Quinapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Lumiracoxib.Approved, Investigational
MacitentanQuinapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Quinapril is combined with Magnesium salicylate.Approved
ManidipineQuinapril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Quinapril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Quinapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinapril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Quinapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Quinapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Quinapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quinapril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Quinapril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quinapril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Quinapril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Quinapril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Quinapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Quinapril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Quinapril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Quinapril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Quinapril.Approved, Investigational
MetyrosineQuinapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilQuinapril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quinapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Quinapril.Approved
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Quinapril.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quinapril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Quinapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Quinapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Quinapril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Quinapril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Quinapril.Approved
MorphineThe risk or severity of adverse effects can be increased when Quinapril is combined with Morphine.Approved, Investigational
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
MoxonidineQuinapril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Quinapril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Quinapril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Quinapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Quinapril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Quinapril is combined with Naftifine.Approved
NaftopidilQuinapril may increase the hypotensive activities of Naftopidil.Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Quinapril.Approved
NaproxenThe risk or severity of adverse effects can be increased when Quinapril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Quinapril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Quinapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Quinapril.Approved, Withdrawn
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Quinapril.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Quinapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Quinapril.Approved
NicorandilNicorandil may increase the hypotensive activities of Quinapril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Quinapril is combined with Niflumic Acid.Approved
NiguldipineQuinapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineQuinapril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quinapril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quinapril.Approved
NitrendipineQuinapril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Quinapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quinapril.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quinapril.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Quinapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Quinapril.Approved
ObinutuzumabQuinapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Quinapril.Withdrawn
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Quinapril.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quinapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Quinapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Olsalazine.Approved
OmapatrilatQuinapril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Quinapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Quinapril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxaprozin.Approved
OxprenololQuinapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxyphenbutazone.Withdrawn
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Quinapril.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Quinapril is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Quinapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Quinapril.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Quinapril.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Quinapril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Quinapril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Quinapril.Approved, Vet Approved
PentoliniumQuinapril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Quinapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Quinapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Quinapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Quinapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Quinapril.Approved
PhenoxybenzamineQuinapril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Quinapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Quinapril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Quinapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Quinapril.Approved
PinacidilQuinapril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Quinapril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Quinapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Quinapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Quinapril.Withdrawn
PolythiazideQuinapril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Quinapril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Quinapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Quinapril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Quinapril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Quinapril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Quinapril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Quinapril.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Quinapril.Investigational
PTC299The risk or severity of adverse effects can be increased when Quinapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.Approved
QuinethazoneQuinethazone may increase the hypotensive activities of Quinapril.Approved
QuinineQuinine may increase the hypotensive activities of Quinapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Quinapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Quinapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Quinapril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Quinapril.Approved
RescinnamineQuinapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinapril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Quinapril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Quinapril.Approved
RilmenidineQuinapril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Quinapril.Approved
RisperidoneQuinapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabQuinapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Quinapril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Quinapril is combined with Ropivacaine.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Quinapril.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Quinapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Quinapril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Quinapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Quinapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Quinapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Quinapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Quinapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Quinapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Quinapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Quinapril.Approved, Investigational, Vet Approved
SelexipagQuinapril may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Quinapril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Quinapril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Quinapril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Quinapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Quinapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Quinapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Quinapril.Approved, Investigational
SitaxentanQuinapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Quinapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Quinapril is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Quinapril.Approved
SpiraprilQuinapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quinapril.Approved
SRT501The risk or severity of adverse effects can be increased when Quinapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Quinapril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Quinapril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Quinapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Quinapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Quinapril.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Quinapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quinapril.Approved, Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Quinapril.Withdrawn
TemocaprilQuinapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Quinapril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Quinapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Quinapril is combined with Teriflunomide.Approved
TerlipressinQuinapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Quinapril.Approved, Vet Approved
ThalidomideThe risk or severity of adverse effects can be increased when Quinapril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Quinapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Quinapril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Tiaprofenic acid.Approved
TiboloneQuinapril may increase the hypotensive activities of Tibolone.Approved
TicrynafenQuinapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Quinapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Quinapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Quinapril.Approved
TipranavirThe serum concentration of Quinapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Quinapril.Approved
TolazolineTolazoline may increase the hypotensive activities of Quinapril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Quinapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Quinapril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Quinapril.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quinapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Quinapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Quinapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Quinapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Quinapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Quinapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Quinapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Quinapril.Approved
TrichlormethiazideQuinapril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinQuinapril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanQuinapril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Quinapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Quinapril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Quinapril is combined with Trisalicylate-choline.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Quinapril.Approved, Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Quinapril.Approved, Investigational
UnoprostoneQuinapril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Quinapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Quinapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Quinapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Quinapril.Approved, Investigational
VinpocetineQuinapril may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineQuinapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Quinapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Quinapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Quinapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Quinapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Do not take with a high-fat meal.
  • Herbs that may attenuate the antihypertensive effect of quinapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of quinapril.
  • Quinapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
References
Synthesis Reference

Om P. Goel, Uldis Krolls, “Crystalline quinapril and a process for producing the same.” U.S. Patent US4761479, issued August, 1982.

US4761479
General References
  1. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004 Jul;27(7):1712-5. [PubMed:15220251 ]
  2. Kieback AG, Felix SB, Reffelmann T: Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. [PubMed:19761414 ]
  3. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001 May 1;87(9):1058-63. [PubMed:11348602 ]
  4. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol. 2004 Feb;44(2):150-7. [PubMed:14747423 ]
  5. Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, Mauri Nicolas JM: Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int Suppl. 1996 Jun;55:S104-6. [PubMed:8743525 ]
  6. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH: Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):130-4. [PubMed:15526248 ]
  7. Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T: Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. [PubMed:12808303 ]
External Links
ATC CodesC09AA06C09BA06
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5597
Blood Brain Barrier-0.9409
Caco-2 permeable-0.8208
P-glycoprotein substrateSubstrate0.8895
P-glycoprotein inhibitor IInhibitor0.7344
P-glycoprotein inhibitor IIInhibitor0.5869
Renal organic cation transporterNon-inhibitor0.8258
CYP450 2C9 substrateNon-substrate0.8594
CYP450 2D6 substrateNon-substrate0.8412
CYP450 3A4 substrateSubstrate0.5356
CYP450 1A2 substrateNon-inhibitor0.8597
CYP450 2C9 inhibitorNon-inhibitor0.6832
CYP450 2D6 inhibitorNon-inhibitor0.8636
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.5347
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5162
Ames testNon AMES toxic0.9091
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable0.9596
Rat acute toxicity2.2690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9763
hERG inhibition (predictor II)Inhibitor0.7176
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer pharmaceuticals ltd
  • Actavis totowa llc
  • Apotex inc
  • Genpharm inc
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
TabletOral
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Accupril 10 mg tablet2.02USD tablet
Accupril 20 mg tablet2.02USD tablet
Accupril 40 mg tablet2.02USD tablet
Accupril 5 mg tablet2.02USD tablet
Quinapril 10 mg tablet1.57USD tablet
Quinapril 20 mg tablet1.57USD tablet
Quinapril 40 mg tablet1.57USD tablet
Quinapril 5 mg tablet1.57USD tablet
Quinapril HCl 10 mg tablet1.27USD tablet
Quinapril HCl 20 mg tablet1.27USD tablet
Quinapril HCl 40 mg tablet1.27USD tablet
Quinapril HCl 5 mg tablet1.27USD tablet
Quinaretic 10-12.5 mg tablet1.27USD tablet
Quinaretic 20-12.5 mg tablet1.27USD tablet
Quinaretic 20-25 mg tablet1.27USD tablet
Accupril 10 mg Tablet0.96USD tablet
Accupril 20 mg Tablet0.96USD tablet
Accupril 40 mg Tablet0.96USD tablet
Accupril 5 mg Tablet0.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1331615 No1994-08-232011-08-23Canada
CA2023089 No2003-01-142010-08-10Canada
US5684016 No1995-05-042015-05-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120-130 °CNot Available
water solubility1 mg/LNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0085 mg/mLALOGPS
logP1.39ALOGPS
logP1.96ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.7ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity119.96 m3·mol-1ChemAxon
Polarizability47.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Tetrahydroisoquinoline
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Culy CR, Jarvis B: Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 2002;62(2):339-85. [PubMed:11817979 ]
  3. Klutchko S, Blankley CJ, Fleming RW, Hinkley JM, Werner AE, Nordin I, Holmes A, Hoefle ML, Cohen DM, Essenburg AD, et al.: Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J Med Chem. 1986 Oct;29(10):1953-61. [PubMed:3020249 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23